These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 33920054)

  • 21. NK Cell Dysfunction and Checkpoint Immunotherapy.
    Bi J; Tian Z
    Front Immunol; 2019; 10():1999. PubMed ID: 31552017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of Lymphocyte Functions in the Microenvironment by Tumor Oncogenic Pathways.
    Seliger B; Massa C
    Front Immunol; 2022; 13():883639. PubMed ID: 35663987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
    Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
    Front Immunol; 2022; 13():891175. PubMed ID: 35990668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insights Gained from Single-Cell Analysis of Immune Cells in the Tumor Microenvironment.
    Ren X; Zhang L; Zhang Y; Li Z; Siemers N; Zhang Z
    Annu Rev Immunol; 2021 Apr; 39():583-609. PubMed ID: 33637019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune Checkpoint Inhibitors: Basics and Challenges.
    Li B; Chan HL; Chen P
    Curr Med Chem; 2019; 26(17):3009-3025. PubMed ID: 28782469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors.
    Budczies J; Bockmayr M; Klauschen F; Endris V; Fröhling S; Schirmacher P; Denkert C; Stenzinger A
    Genes Chromosomes Cancer; 2017 Aug; 56(8):651-659. PubMed ID: 28466543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Turning Cold into Hot: Firing up the Tumor Microenvironment.
    Duan Q; Zhang H; Zheng J; Zhang L
    Trends Cancer; 2020 Jul; 6(7):605-618. PubMed ID: 32610070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy.
    Guram K; Kim SS; Wu V; Sanders PD; Patel S; Schoenberger SP; Cohen EEW; Chen SY; Sharabi AB
    Front Immunol; 2019; 10():491. PubMed ID: 30936880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrative insights and clinical applications of single-cell sequencing in cancer immunotherapy.
    Liu Z; Li H; Dang Q; Weng S; Duo M; Lv J; Han X
    Cell Mol Life Sci; 2022 Oct; 79(11):577. PubMed ID: 36316529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune checkpoint signaling and cancer immunotherapy.
    He X; Xu C
    Cell Res; 2020 Aug; 30(8):660-669. PubMed ID: 32467592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints.
    Baghbani E; Noorolyai S; Shanehbandi D; Mokhtarzadeh A; Aghebati-Maleki L; Shahgoli VK; Brunetti O; Rahmani S; Shadbad MA; Baghbanzadeh A; Silvestris N; Baradaran B
    Life Sci; 2021 Oct; 282():119826. PubMed ID: 34265363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery.
    Shadbad MA; Asadzadeh Z; Derakhshani A; Hosseinkhani N; Mokhtarzadeh A; Baghbanzadeh A; Hajiasgharzadeh K; Brunetti O; Argentiero A; Racanelli V; Silvestris N; Baradaran B
    Biomed Pharmacother; 2021 Nov; 143():112213. PubMed ID: 34560556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. G protein-coupled receptor-mediated signaling of immunomodulation in tumor progression.
    Qiu GH; Yu B; Ma M
    FASEB J; 2024 Jul; 38(14):e23829. PubMed ID: 39017658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting immune cells for cancer therapy.
    Gun SY; Lee SWL; Sieow JL; Wong SC
    Redox Biol; 2019 Jul; 25():101174. PubMed ID: 30917934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune checkpoints and cancer development: Therapeutic implications and future directions.
    Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
    Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging strategies for combination checkpoint modulators in cancer immunotherapy.
    Popovic A; Jaffee EM; Zaidi N
    J Clin Invest; 2018 Aug; 128(8):3209-3218. PubMed ID: 30067248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.
    Rotte A; Jin JY; Lemaire V
    Ann Oncol; 2018 Jan; 29(1):71-83. PubMed ID: 29069302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting Adenosine Receptor Signaling in Cancer Immunotherapy.
    Sek K; Mølck C; Stewart GD; Kats L; Darcy PK; Beavis PA
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30513816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint.
    Zhou X; Du J; Liu C; Zeng H; Chen Y; Liu L; Wu D
    Front Immunol; 2021; 12():688215. PubMed ID: 34305920
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.